NCT03316573 2026-02-10Pembrolizumab in Neoplasms or LymphomasDana-Farber Cancer InstitutePhase 2 Suspended18 enrolled 16 charts
NCT02523040 2025-12-10Lenalidomide for Adult Histiocyte DisordersDana-Farber Cancer InstitutePhase 2 Active not recruiting12 enrolled 14 charts